47 results about "Escherichia infection" patented technology

The invention relates to a holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry. The compound composition is prepared from the following raw materials in parts by weight: 3 to 30 parts of antibacterial drug, and 5 to 200 parts of holly bark. The raw materials are uniformly mixed to prepare powder, tablets, oral liquid or granules which are added into animal feed in a ratio of 0.1 to 5g / kg feed addition amount for feeding, and the drug resistances of bacteria to the antibacterial drug can be reversed, so that the treatment effect of antibacterial drugs can be improved, the administration cost can be greatly reduced, and higher economic benefit can be created for farmers.

The invention discloses a bacteriostatic nourishing liquid for skin, which relates to a medicine, especially to an external medicinal liquid. The bacteriostatic nourishing liquid comprises the following raw materials by weight: 4 to 6% of phellodendron, 4 to 6% of coptis, 0.8 to 1.2% of salicylic acid and 86.8 to 91.2% of ethanol with a concentration of 70 to 80%. The bacteriostatic nourishing liquid is prepared by percolating phellodendron and coptis powder with ethanol, collecting percolate, dissolving salicylic acid into the percolate, carrying out uniform mixing with stirring and then successively carrying out filling, sealing and packaging. The bacteriostatic nourishing liquid provided by the invention overcomes the problem that traditional drugs used to treat infection by Staphylococcus aureus, Candida albicans and Escherichia coli caused by moth bites do not have ideal treatment effects and cannot thoroughly treat skin infection after long-term usage.

The invention discloses a herbal veterinary medicine for preventing and treating chicken heat-toxin symptoms caused by Escherichia coli infection. The herbal veterinary medicine comprises the following raw materials: on the basis of the amount of crude drugs, 30 to 90 g of gypsum, 3 to 20 g of honeysuckle flower, 2 to 30 g of figwort root, 2 to 15 parts of baical skullcap root, 2 to 15 g of raw rehmannia root, 2 to 15 g of weeping forsythia capsule, 2 to 15 g of cape jasmine, 2 to 15 g of Chinese gentian, 2 to 30 g of Gueldenstaedtia multiflora Bunge., 2 to 40 g of isatis root, 2 to 15 g of common anemarrhena rhizome and 2 to 15 g of dwarf lilyturf tuber. The herbal veterinary medicine is a granule which further comprises an excipient. A preparation method for the summer-heat-removing granule comprises the following steps: (1) extracting the above-mentioned raw materials so as to prepare extract powder; (2) adding the excipient and carrying out uniform mixing; and (3) successively carrying out granulation, drying and split charging so as to obtain the finished granule. The granule provided by the invention is named as summer-heat-removing granule, is capable of clearing heat, removing toxins, nourishing yin and checking dysentery and has the advantages of a substantial effect, convenience in administration and no toxic and side effects.

The invention belongs to the field of cell biology, and particularly relates to an application of an antibacterial peptide in the in-vitro inhibition of Escherichia coli. The antibacterial peptide selected by the invention is a natural antibacterial peptide Esculentin-1A, and the amino acid sequence information of the antibacterial peptide Esculentin-1A is shown as SEQ ID NO.1. In the research process, it is found that the antibacterial peptide Esculentin-1A and citric acid are mixed according to a mass ratio of (7-10):(2-5), and in-vitro tests prove that the inhibition of the mixture on Escherichia coli reaches 99% or more. The antibacterial peptide and citric acid are mixed for use for the first time, and a new research and development direction is provided for the development of drugs related to the treatment of symptoms such as cholecystitis and ovaritis caused by Escherichia coli infection.

The invention relates to a Chinese and western drug for treating avian escherichia coli diseases. The invention is characterized in that the Chinese and western drug comprises the components by weight parts as follows: rhubarb is 10 to 30 parts, radix scutellariae is 5 to 15 parts, coptis roots are 1 to 5 parts, radix isatidis is 1 to 5 parts, and enrofloxacin is 0.5 to 5 parts. The invention has a preparation method as follows: (1) the components are got by weight parts as follows: the rhubarb is 10 to 30 parts, the radix scutellariae is 5 to 15 parts, the radix isatidis is 1 to 5 parts, and the radix isatidis is 1 to 5 parts; (2) purified water which is 2 to 3 times the weight of the total quantity of all components is added, and concentrated solution is obtained after diacolation, evaporation and concentration, wherein, the relative density of the concentrated solution is 1.05 to 1.2; (3) the enrofloxacin which is 0.1 to 1 time the weight of the concentrated solution is added in the concentrated solution, and the purified water which is 2 to 5 the weight of the concentrated solution is added, so that the Chinese and western drug is made. The invention has strengthening efficacy after extraction and separation, effectively treats chicken escherichia infection, and reduces the economic loss of raising households. The Chinese and western drug realizes the reasonable collocation and combination by selecting various active ingredients, the cost is low, the curative effect is good, the cure rate is high, and the safety and the reliability are realized.

The present invention relates to a long-tailed virus family phage Esc-COP-9 (entrusted number: KCTC 13131BP) isolated from nature, characterized in that it carries a genome with the ability to specifically kill Escherichia coli and is marked with sequence number 1, And the present invention also relates to a method for preventing and treating pathogenic Escherichia coli infection by using the composition containing the phage as an active ingredient.

The present invention discloses a granule for treatment of heat toxin symptom caused by chicken escherichia coli infection. The raw material ratio by crude medicines includes: 30-90g of gypsum, 3-20g of honeysuckle, 2-30g of figwort root, 2-15g of baical skullcap root, 2-15g of dried radix rehmannia, 2-15g of fructus forsythiae, 2-15g of fruit of cape jasmine, 2-15g of gentiana scabra bunge, 2-30g of bunge corydalis herb, 2-40g of isatis root, 2-15g of rhizoma anemarrhena, and 2-15g of radix ophiopogonis. The granule also includes an excipient. The preparation method of the granule includes: (1) extracting the prescription medicine to make extract powder; (2) adding the excipient and mixing; and (3) granulating, drying and packaging to get finished products. The granule of the present invention has a trade name of clearing and releasing granule, has the effect of clearing heat and detoxifying, is significant in effects and easy to take, and has no toxic side effects.

The invention relates to an echinacea extract and a preparation method of the echinacea extract. The echinacea extract provided by the invention is obtained through carrying out twice extraction on echinacea medicinal materials by alkaline ethanol solution and lysozyme; and in the product, the polysaccharide content is greater than or equal to 21.50 percent, the polyphenol content is greater than or equal to 8.10 percent, and the chicoric acid content is greater than equal to 5.00 percent. Because the polyphenol content and the chicoric acid content of the echinacea extract are obviously increased, the echinacea extract is prepared into ordinary preparations including powder or oral liquid and the like, and the curative effect is greatly improved. In a compound preparation processed by the echinacea extract and bacteriolysant according to a consumption ratio being 3:1, active ingredients of echinacea and lysozyme totally account for 20 percent, wherein the consumption ratio of the echinacea extract to the lysozyme is (4-1):1, auxiliary materials of cane sugar account for 64 percent, and dextrin accounts for 16 percent. The compound preparation has the functions of improving the immunity of live stock and realizing the sterilization and antivirus functions, and can be used as medicine for preventing and treating animal diseases, particularly chicken diseases caused by escherichia coli infection.

The present invention relates to blood group A / B / H determinant on Type 1 Core glycosphingolipids chains as recognition point for the FedF protein of F18-fimbriated Enterotoxigenic and verotoxinogenic Escherichia coli and the use of compounds comprising such determinants for the treatment of F18′ E. coli infections in pigs and in screening methods.

The invention discloses a gene encoding recombinant porcine interleukin-22. The invention also discloses a recombinant expression vector containing the recombinant gene, a transgenic cell system, a transgenic recombinant bacterium and a host cell. The invention also discloses recombinant porcine interleukin 22 and its extraction and purification method. The invention also discloses the application of the recombinant plasmid pET-32a(+)-pIL-22, the recombinant strain and the recombinant protein in anti-apoptosis and anti-Escherichia coli infection. The vector pET‑32a (+) for expressing recombinant porcine interleukin 22 constructed by the present invention contains a His tag, and the recombinant porcine interleukin 22 protein extracted from Escherichia coli is connected with the His tag, and highly purified recombinant porcine interleukin can be obtained through the His column 22 protein; the expression yield of recombinant porcine interleukin 22 protein was counted by Quantity One software, and the purity was as high as 95.7%.

The invention discloses a pH-regulating self-assembled antibacterial peptide, its preparation method and application. The sequence of the antibacterial peptide SAP is shown in SEQ ID No.1. Design a histidine His-functionalized β-sheet peptide containing hydrophobic amino acids Trp and Val. His and Trp are respectively placed at the non-hydrogen bond sites adjacent to the β-sheet structure, distributed in a diagonal form, and other hydrogen bond sites distribute equal amounts of His and Val, respectively, D Pro-Gly acts as a β-turn to connect the two peptide chains of the β-sheet structure. The freeze-dried powder of the antimicrobial peptide is dissolved in ultrapure water with pH=6.0, and the monomers of the antimicrobial peptide fully self-assemble into nanoparticles in the aqueous solution. The antimicrobial peptide is used in the preparation of medicines for treating Escherichia coli infectious diseases in acidic environment. Antimicrobial peptides exert effective antibacterial effects in acidic environments, have low hemolytic toxicity, and have good salt ion stability, which overcomes the weakness of low stability of natural antimicrobial peptides.

The invention discloses a preparation method of a shiga-like toxin Stx1B oral vaccine, which concretely comprises the steps of: cloning a shiga-like toxin Stx1B gene, building a recombinant expression vector containing the Stx1B gene, then preparing a transgenic plant, and finally preparing the shiga-like toxin Stx1B oral vaccine. The prepared shiga-like toxin Stx1B oral vaccine can be directly and orally taken to immunize and can effectively prevent the escherichia coli O157:H7 infection, moreover, the orbidity of edema disease of a pig is reduced, and the death efficiency is also reduced at the same time.